Targeting PI3K signalling in cancer: opportunities, challenges and limitations
- PMID: 19629070
- DOI: 10.1038/nrc2664
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Abstract
There are ample genetic and laboratory studies that suggest the PI3K-Akt pathway is vital to the growth and survival of cancer cells. Inhibitors targeting this pathway are entering the clinic at a rapid pace. In this Review, the therapeutic potential of drugs targeting PI3K-Akt signalling for the treatment of cancer is discussed. I focus on the advantages and drawbacks of different treatment strategies for targeting this pathway, the cancers that might respond best to these therapies and the challenges and limitations that confront their clinical development.
Similar articles
-
[PI3K-AKT-mTOR pathway inhibitors].Bull Cancer. 2006 Jan;93(1):19-26. Bull Cancer. 2006. PMID: 16455502 Review. French.
-
[Dermatological implications of the PI3K pathway].Ann Dermatol Venereol. 2015 Oct;142(10):622-3. doi: 10.1016/j.annder.2015.04.019. Epub 2015 May 19. Ann Dermatol Venereol. 2015. PMID: 26001484 Review. French. No abstract available.
-
Development of PI3K inhibitors: lessons learned from early clinical trials.Nat Rev Clin Oncol. 2013 Mar;10(3):143-53. doi: 10.1038/nrclinonc.2013.10. Epub 2013 Feb 12. Nat Rev Clin Oncol. 2013. PMID: 23400000 Review.
-
Current status and challenges associated with targeting mTOR for cancer therapy.BioDrugs. 2009;23(2):77-91. doi: 10.2165/00063030-200923020-00002. BioDrugs. 2009. PMID: 19489650 Review.
-
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):335-42. doi: 10.1016/j.clml.2014.01.007. Epub 2014 Feb 7. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24650973 Free PMC article. Review.
Cited by
-
Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma.Cancer Biol Med. 2021 May 7;18(3):721-33. doi: 10.20892/j.issn.2095-3941.2020.0430. Cancer Biol Med. 2021. PMID: 33960177 Free PMC article.
-
Mitochondria in cancer.Cell Stress. 2020 May 11;4(6):114-146. doi: 10.15698/cst2020.06.221. Cell Stress. 2020. PMID: 32548570 Free PMC article. Review.
-
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.J Clin Invest. 2013 Jun;123(6):2551-63. doi: 10.1172/JCI66343. Epub 2013 May 1. J Clin Invest. 2013. PMID: 23635776 Free PMC article.
-
PI3K mutations in breast cancer: prognostic and therapeutic implications.Breast Cancer (Dove Med Press). 2015 May 15;7:111-23. doi: 10.2147/BCTT.S60696. eCollection 2015. Breast Cancer (Dove Med Press). 2015. PMID: 26028978 Free PMC article. Review.
-
Ultrahigh resolution lipid mass spectrometry imaging of high-grade serous ovarian cancer mouse models.Front Chem. 2024 Jan 8;11:1332816. doi: 10.3389/fchem.2023.1332816. eCollection 2023. Front Chem. 2024. PMID: 38260043 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous